Table 2 Bivariate regression analysis between patients with baseline dp-ucMGP <5000 and those >5000 pM
Baseline dp-ucMGP <5000 N = 41 | Baseline dp-ucMGP >5000 N = 9 | P-value | |
|---|---|---|---|
Age (years), median (IQR) | 69.0 (56.5; 76.5) | 80.0 (57.0; 82.5) | 0.18 |
Gender, male n (%) | 28 (68.3) | 2 (22.2) | 0.02 |
Dialysis vintage (months), median (IQR) | 43.0 (20.5; 104.0) | 82.0 (41.0; 134.0) | 0.18 |
Diabetes, n (%) | 16 (39.0) | 2 (22.2) | 0.46 |
Hypertension, n (%) | 34 (82.9) | 4 (44.4) | 0.03 |
Smoking, n (%) | 6 (14.6) | 2 (22.2) | 0.62 |
Calcification score, median (IQR) | 7.0 (2.0; 12.5) | 13.0 (2.5; 21.0) | 0.25 |
NCBB, n (%) | 16 (39.0) | 4 (44.4) | 1.00 |
Residual diuresis, n (%) | 5 (12.2) | 1 (11.1) | 1.00 |
Calcium dose (tablets of 600 mg), median (IQR) | 1.0 (1.0; 3.0) | 1.0 (0.0; 1.0) | 0.055 |
Alfacalcidol dose (μg), median (IQR) | 0.75 (0.00; 1.25) | 1.0 (0.5; 5.0) | 0.08 |
Serum phosphate (mg/dl), median (IQR) | 3.9 (3.3; 4.8) | 3.90 (2.75; 4.40) | 0.29 |
Serum calcium (mg/dl), median (IQR) | 9.1 (8.8; 9.3) | 9.2 (8.8; 9.6) | 0.40 |
PTH (pg/ml), median (IQR) | 163.0 (95.2; 260.0) | 197.0 (165.5; 397.0) | 0.27 |
LDL cholesterol (mg/dl), median (IQR) | 92.0 (77.0; 113.0) | 92.0 (67.0; 113.0) | 0.82 |
BMI, median (IQR) | 25.6 (22.8; 27.8) | 26.16 (23.35; 33.56) | 0.18 |
URR, median (IQR) | 74.0 (71.0; 78.0) | 77.0 (75.0; 80.5) | 0.08 |
Albumin, median (IQR) | 39.0 (37.0; 41.5) | 36.5 (34.0; 39.0) | 0.046 |
CAD, n (%) | 11 (26.8) | 3 (33.3) | 0.70 |
Cinacalcet, n (%) | 1 (2.4) | 1 (11.1) | 0.33 |
Previous acenocoumadin, n (%) | 4 (9.8) | 2 (22.2) | 0.29 |
PTHX, n (%) | 2 (4.9) | 0 (0.0) | 1.00 |
Recent fracture, n (%) | 0 (0.0) | 3 (33.3) | 0.004 |